Table 3 Clinical features and hospital course of children with rheumatic diseases hospitalized with COVID-19
From: Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases
Patient No. | Baseline features | Immuno-suppression management | Symptoms | Inpatient care and therapies | Rheumatic disease flare diagnosisc | Flare management | Other complications | Final outcome | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Agea/Sex | Rheumatic disease diagnosis | Active disease | Comorbidities | Immuno-suppression regimen | ICU LOSb | Total LOSb | No. of hospitalizations | Remdesivir | Convalescent plasma | Respiratory support | IV antibiotics | Anticoagulation | |||||||
1 | 16/F | SLE (with ILD) | N | HCQ, PDN 2.5 mg daily, MMF, RTX | Continued | Fever, cough, dyspnea | 0 | 2 | 1 | N | N | N | Y | N | None | Pneumonia | Survived | ||
2 | 19/F | SLE (with LN) | Y | HTN | HCQ, PDN 40 mg daily | Continued | Fever, cough, dyspnea, anosmia/ageusia | 1 | 5 | 2 | N | N | LFNC | Y | Y | Before | IVMP | Pneumonia, AKI | Survived |
3 | 17/F | Overlap sd. (with ILD) | Y | HCQ, PDN 30 mg daily, MMF, IV CYC | MMF and HCQ held | Fever, sore throat, dyspnea, myalgia, diarrhea, vomiting | 4 | 8 | 1 | Y | Y | HFNC | Y | Y | Before | Increased PDN dose | Survived | ||
4 | 19/F | SLE+ RA | Y | HCQ, PDN 10 mg daily, MTX, MMF, RTX | Continued | Myalgia, chest pain | 0 | 4 | 1 | N | N | N | N | N | Before | IVMP, increased PDN dose | Survived | ||
5 | 19/F | JIA | Y | Tofacitinib | Continued | Fever, abdominal pain | 0 | 2 | 1 | N | N | N | Y | N | None | Urosepsis | Survived | ||
6 | 19/F | SLE (with LN) | Y | Hyperparathyroidism, LVH, HTN, anemia of chronic disease, s/p renal transplant | HCQ, PDN 5 mg daily, tacrolimus, MMF, RTX | MMF held | Fever, cough, diarrhea, anosmia/ageusia, rhinorrhea, fatigue, chest pain, rash | 4 | 17 | 1 | N | Y | HFNC | Y | Y | Concurrent | IVMP, increased PDN dose, IV CYC | Renal failure requiring HD, pneumonia | Survived |
7 | 17/M | SLE+ MAS | Y | HTN | HCQ, PDN 20 mg daily, MMF, ANK | ANK heldd | Fever, myalgias, headaches, vomiting, diarrhea, rash f | 0 | 4 | 1 | N | N | N | Y | N | After | IVMP, increased PDN dose | C. difficile colitis | Survived |
8 | 16/M | Sarcoidosis (with ILD) | Y | SCD, Cholestasis, pulmonary HTN | PDN 30 mg daily, MMF | MMF held | Myalgia | 0 | 5 | 1 | Y | N | LFNC | N | Y | None | Survived | ||
9 | 14/M | Overlap sd. (with LN) | Y | Asthma, HTN | HCQ, PDN 60 mg daily, MMF RTX | Continued | Rash, chest pain | 0 | 3 | 1 | N | N | N | N | Y | None | Conjunctivitis 3 weeks post-admissione | Survived | |
10 | 14/F | AAV+ anti-GBM disease (with RLD) | Y | ESRD on PD, HTN, acquired IgG deficiency | PDN 5 mg daily, leflunomide, RTX | Leflunomide held | Fever, fatigue, sore throat, nausea/vomiting, diarrhea, abdominal pain, dyspnea, chest pain, rash, myalgias f | 26 | 41 | 3 | N | N | MV/ ECMO | Y | N | After | PLEX, IVMP, IVIG, IV CYC, RTX | Pneumonia, C. difficile colitis, cytokine storm requiring ANK and TCZ | Deceased |